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SUMMARY
Background. This study assessed the effect of eperisone + physical therapy compared 
with physical therapy alone on the alleviation of pain and disability experienced by 
patients with tension-type cervicalgia. 
Methods. Patients with tension-type cervicalgia were randomized to eperisone + phy -
sical therapy (Group A) or physical therapy alone (Group B). Patients were assessed at 
baseline (T0), after 4-weeks’ treatment (T1), and at 2 months’ follow-up (T2). Outcome 
measures included the Numerical Rating Scale, the Italian version of the Neck Pain 
and Disability Scale, the Short Form-McGill Pain Questionnaire, and the Italian 
version of the Neck Disability Index. 
Results. Ninety-eight patients (50 patients in Group A and 48 patients in Group B) 
completed the study. Pain and disability scores for all outcome measures were signifi-
cantly lower at both T1 and T2 for patients in Group A compared with Group B (all 
p<0.001). A small, improvement between T1 and T2 was observed in Group A patients 
but not in Group B patients, and significantly more Group B than Group A patients 
were worse at 2 months’ follow-up (all p<0.001). 
Conclusions. Eperisone in synergy with physical therapy can be a valuable tool in the 
therapeutic management of patients suffering from tension-type cervicalgia.
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INTRODUCTION
Neck pain is a disabling condition, with sufferers often 
experiencing periods of remission and exacerbation; for 
most individuals, complete resolution of symptoms and 
disability is not achieved (1).
Neck pain has been ranked by the Global Burden of Disease 
Study 2010 as the fourth leading cause of years lived with 
disability (2). Age, gender and genetics have been identified 
as non-modifiable risk factors for neck pain3 and stress has 
been identified as a modifiable risk factor (4). More women 
than men experience neck pain and its prevalence peaks in 
middle age (3). The annual prevalence of neck pain has been 
estimated to range between 15% and 70%, demonstrating 
the substantial heterogeneity in reported prevalence rates 
(3, 5, 6).
Cervicalgia is localized pain that occurs towards the rear 
or side of the cervical spinal vertebrae, with sufferers expe-
riencing either a sharp, stabbing pain or a dull, persistent 
pain in the neck, upper back or shoulders (7, 8). Symp-
toms of cervicalgia may include stiffness or spasms in neck 
muscles, movement-related pain when rotating in all direc-
tions, constant ache in the neck, tightness around the neck/
upper back, which may be tender to touch, and headaches 
(7, 9, 10). Symptoms of cervicalgia may disappear within a 
few weeks, however, medical treatment may be required if 
the pain persists.
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Eperisone hydrochloride (40-ethyl-2-methyl-3-piperidino-
propiophenone hydrochloride) is an analgesic and centrally 
acting muscle relaxant with a novel mechanism for the treat-
ment of spasticity, muscle contraction and associated pain. 
Eperisone is indicated in the treatment of spastic paralysis 
caused by cerebrovascular disorders, spastic spinal paraly-
sis, and spastic multiple sclerosis, and for the improvement 
of muscular contractions secondary to osteo-arthro-muscu-
lar pathologies (cervical arthrosis, scapulohumeral periar-
thritis, lumbosciatalgia, and myalgias) (11). 
Treatment with eperisone alleviates muscle stiffness and pain 
caused by muscle spasm. Its mechanisms of action include: 
skeletal muscle relaxation, hemodynamic action, and anal-
gesic activity, thereby offering a multimodal approach to 
pain management (12).
A systematic literature review found that eperisone may 
offer an effective treatment choice for patients with low back 
pain with minimal adverse effects and improved paraspi-
nal blood flow, although the smaller sample size and short-
er duration of the studies assessed prevented its definitive 
recommendation for the treatment of low back pain (13). It 
is therefore reasonable to suggest that eperisone may also be 
effective for the treatment of tension-type cervicalgia.
The aim of the current study was to assess the effect of 
eperisone + physical therapy compared with physical ther-
apy alone on the alleviation of pain and disability experi-
enced by patients with tension-type cervicalgia.
MATERIALS AND METHODS
Patients
Outpatients with tension-type cervicalgia who were under-
going treatment at the Physical Medicine and Rehabilita-
tion Clinic of the University Hospital “P. Giaccone”, Paler-
mo, were included in the study. Patients were consecutively 
enrolled from March 2016 to April 2017 and were includ-
ed in the study if they were aged between 20 and 70 years, 
affected by cervicalgia due to subcutis tension in the tempo-
ral muscle (from 4 weeks to 12 weeks temporal classifica-
tion according to Crue and Pinsky) (14), had a positive 
trigger point, and had undergone a 7-day wash-out peri-
od from nonsteroidal anti-inflammatory drugs (NSAIDs) 
and myorelaxants. Exclusion criteria included: radiculopa-
thy, rheumatic disease, presence of fracture, epilepsy, pace 
maker, chronic renal insufficiency and hepatic insufficiency, 
pregnancy, and neoplasm. Written, informed consent was 
obtained from the patients prior to study entry. The study 
was approved by the local Institutional Review Board (Ethi-
cal Committee of Palermo: 1 session of approval 16/05/2018 
n. 05/2018) in accordance with the ethical principles stated 
in the Declaration of Helsinki. The study meets the ethical 
standards of the journal (15).
Patients were randomized in two groups and received either 
eperisone + physical therapy (Group A) or physical ther-
apy alone (Group B). For patients in Group A, eperisone 
hydrochloride 100 mg was given twice a day for 15 days + 20 
sessions of physical therapy, which included transcutaneous 
electrical nerve stimulation (TENS) and CO2 Laser on the 
cervical rachis 5 days a week for a total of 4 weeks. Patients 
in Group B, who only received physical therapy, were treat-
ed with 20 sessions TENS and CO2 Laser on the cervical 
rachis 5 days a week for a total of 4 weeks.
Patients were assessed at baseline (T0), at the end of the 
4-week treatment period (T1), and at follow-up, 2 months 
later (T2). At each study visit, patients’ pain and disability 
were assessed via a clinical examination and via question-
naires including the Numerical Rating Scale (NRS), the Ital-
ian version of the Neck Pain and Disability Scale (NPDS) 
(16), the Short Form-McGill Pain Questionnaire (SF-MG-
PQ) (17), and the Italian version of the Neck Disability 
Index (NDI) (18).
The NRS is based on a scale from 0–10, in which “0” is the 
absence of pain and “10” is the worst pain the patient can 
imagine. Patients are asked to assign a score to the intensity 
of their pain.
The NPDS is a region-specific measurement scale that was 
developed based on the Million Visual Analogue Scale (19) 
and recommended by Wheeler and colleagues (20) for 
cervical pain and associated disability. It is a self-adminis-
tered questionnaire consisting of 20 items which assess four 
dimensions of neck pain: neck pain/intensity, neck prob-
lems, effects of neck pain on emotions, and interference with 
activities of daily life (16). The 20 items are scored on a range 
of 0 to 5, with a highest total score of 100 (= maximal pain).
The SF-MGPQ is a useful tool to investigate the quality of 
pain. Designed in 1987, it is the short version of the MGPQ 
and allows individuals to identify the characteristics of the 
pain they experience, to detect minor clinical changes and 
to reflect further on the expectations and the unexpect-
ed features of pain17. Patients are asked to describe their 
perception of pain according to its intensity (none = 0, mild 
= 1, moderate = 2, and severe = 3).
The NDI questionnaire is designed to assess how neck pain 
affects a patients’ ability to manage everyday life activities. 
Calculation of the NDI score is obtained by adding up the 
separate scores of the 10 sections (each section is scored 
from 0 to 5 where 0 relates to pain having no effect and 5 is 
pain having the highest impact on daily activities of life); the 
highest total score is 50 (18).
Changes in the NRS, NPDS, SF-MGPQ, and NDI for 
each patient were assessed at the end of the 4-week treat-
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ment period (T1) and after the 2-month follow-up period 
(T2). Patients with a reduction in the questionnaire score 
compared with the previous assessment were classified as 
“improved”. If there were no changes, they were described 
as “unchanged”. If a patients’ pain/disability had worsened 
compared with the previous assessment (i.e., an increase in 
the questionnaire score), they were classified as “worsened”.
Statistical analysis
Statistical analysis was performed using the SPSS Statistical 
Package software, ver. 20.0 (IBM Corp., Armonk, NY, USA).
Demographics, clinical and symptom-related data, and treat-
ment type are depicted in tables that show absolute frequen-
cies and percentage relative frequencies for qualitative vari-
ables, and mean/median values, standard deviations, and 
minimum and maximum values for quantitative variables.
Variations in pain and disability based on the NRS, NPDS, 
SF-MGPQ, and NDI scores were analyzed between the two 
treatment types using a generalized linear model (repeat-
ed measures analysis of variance). The paired sample t-test 
was used to assess pre- and post-treatment changes in each 
patient. The unpaired sample t-test assessed the differences 
between treatment groups. Where required, corrections for 
multiple comparisons were applied to the p-value.
To establish if there was an association between the admin-
istered therapy and the worsening of pain and disabili-
ty during the follow-up period, a χ2 test was applied with 
correction for continuity. The relative risk (RR) was also 
calculated with a 95% confidence interval (95% CI). The 
RR is the ratio of the incidence of cases with symptom wors-
ening in Group B (physical therapy only) over the incidence 
of cases with symptom worsening in Group A (eperisone + 
physical therapy).
Values of p<0.05 were considered significant. 
RESULTS
In total, 98 patients (50 patients treated with eperisone + 
physical therapy and 48 patients treated with physical ther-
apy alone) were eligible for and included in the study; all 
patients completed the study and were included in the 
assessment.
Patient demographics and clinical features at baseline are 
shown in table I. Mean patient age was 41.6 years (range 
24–69 years) and 69.4% of patients were female. At baseline, 
there were no significant between-treatment group differ-
ences in age, gender or in the patient outcome measures of 
the NRS, NPDS, and SF-MGPQ. Baseline NDI was signifi-
cantly different for the two treatment groups (32.8 versus 
30.4 for Group A versus Group B; p<0.001) (table I).
The change from baseline in pain and disability scores 
based on the NRS, NPDS, SF-MGPQ, and NDI ques-
tionnaires after 4-weeks’ treatment and after 2-months’ 
follow-up are shown in figure 1. For patients treated with 
eperisone + physical therapy, pain and disability scores 
decreased significantly from T0 to T1 and from T1 to T2 for 
most outcome measures (all p<0.001), with the exception 
of the decrease in NRS score between T1 and T2, which was 
not significant. Pain and disability scores also decreased 
significantly from T0 to T1 for patients treated with physical 
therapy alone (p<0.001 for all outcome measures), however 
these increased significantly between T1 to T2 (p<0.005 for 
NRS and NPDS; p<0.001 for SF-MGPQ and NDI) show-
ing that improvements in neck pain were not sustained after 
completion of the treatment.  
Importantly, pain and disability scores for all patient outcome 
measures were significantly lower at both T1 and T2 for 
patients treated with eperisone + physical therapy compared 
with physical therapy alone (all p<0.001 for NRS, NPDS, 
SF-MGPQ, and NDI). The total change in pain and disabili-
ty scores from T0 to T2 was also significantly lower for patients 
treated with eperisone + physical therapy versus physical 
therapy alone (-4.9 versus -2.2 for the NRS, -37.0 versus -18.0 
for the NPDS, -9.7 versus -5.6 for the SF-MGPQ, and -24.6 
versus -16.1 for the NDI, respectively; all p<0.001).
For an overview of changes in pain and disability scores 
observed for all outcome measures (NRS, NPDS, SF-MG-
PQ, and NDI) during the study period, the percentage 
change between assessments was calculated (table II). 
Patients treated with eperisone + physical therapy not only 
maintained improvements observed after treatment (from 
T0 to T1), they also benefited from a further, albeit small, 
improvement between T1 and T2. Conversely, although the 
percentage change in pain and disability scores decreased 
from baseline to treatment end for patients treated with 
physical therapy alone (from T0 to T1), this was not main-
tained at the 2-month follow-up assessment (from T1 to T2) 
with the increase in questionnaire scores showing a worsen-
ing of patients’ pain/disability compared with the previous 
assessment. For all outcome measures, there was a greater 
decrease in total percentage change for patients treated with 
eperisone + physical therapy than physical therapy alone.
table III shows the change in the NRS, NPDS, SF-MG-
PQ, and NDI scores of each patient assessed after 4-weeks’ 
treatment and at 2-months’ follow-up compared with their 
previous assessment. For all patients, symptoms of pain and 
disability improved from baseline after 4-weeks’ treatment 
regardless of treatment type. Symptoms of pain and disabil-
ity either improved or were unchanged at the 2-month 
follow-up assessment compared with the end of the 4-week 
treatment period for most patients treated with eperisone + 
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Figure 1. Patient outcome measures at T0 (baseline), T1 (after 4 weeks’ treatment), and T2 (after 2-months’ follow-up) for the 
(a) Numerical Rating Scale (b) Neck Pain and Disability Scale (c) Short Form – McGill Pain Questionnaire, and (d) Neck Disability 
Index. Abbreviations: ns: not significant.
Table I. Patient demographics and clinical features at baseline.
Total patients (n=98) Eperisone + physical therapy 
(n=50)
Physical therapy (n=48) p-valuea
Gender, n (%)
 Females 68 (69.4%) 37 (74.0%) 31 (64.6%) ns
 Males 30 (30.6%) 13 (26.0%) 17 (35.4%) ns
Age (years)b 41.6 ±9.5
(24–69)
42.9 ±10.1
(24–69)
40.2 ±8.7
(25–56)
ns
NRSc 7.2 ±0.7
(5–8)
7.2 ±0.7
(6–8)
7.2 ±0.8
(5–8)
ns
NPDSc 57.9 ±6.5
(41–69)
58.0 ±6.6
(41–67)
57.8 ±6.6
(41–69)
ns
SF-MGPQc 15.1 ±1.8
(11–18)
15.0 ±1.8
(11–18)
15.1 ±1.8
(11–18)
ns
NDIc 31.6 ±3.4
(26–42)
32.8 ±3.7
(27–42)
30.4 ±2.6
(26–35)
<0.001
aUnpaired sample t-test was used to assess the differences between treatment groups. The p-values have been corrected with procedures for multiple 
comparisons.
bmean ±SD (min–max).
cmedian ±SD (min–max).
Abbreviations: n: number; NDI: Neck Disability Index; NPDS: Neck Pain and Disability Scale; NRS: Numerical Rating Scale; ns: not significant; SD: 
standard deviation; SF-MGPQ: Short Form – McGill Pain Questionnaire.
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physical therapy (90% for NRS, 92% for NPDS, 88% for 
SF-MGPQ, and 86% for NDI). For patients treated with 
physical therapy alone, significantly more were worse at 
follow-up (T2) when compared with patients treated with 
eperisone + physical therapy (58.3% versus 10.0% for NRS, 
p<0.001 [RR=5.8; 95% CI: 2.5–13.9]; 60.4% versus 8.0% 
for NPDS, p<0.001 [RR=7.6; 95% CI: 2.9–19.9]; 70.8% 
versus 12.0% for SF-MGPQ, p<0.001 [RR =5.9; 95% 
CI: 2.7–12.8]; and 91.7% versus 14.0% for NDI, p<0.001 
[RR=6.6; 95% CI: 3.3–13.1]).
No adverse drug events or reactions were reported.
DISCUSSION
This was a monocentric clinical study on outpatients with 
tension-type cervicalgia who were treated with a muscle 
relaxant drug (eperisone hydrochloride) + physical ther-
apy versus physical therapy alone. Our results show that 
patients treated with eperisone + physical therapy not only 
maintained the significant improvement in pain and disabil-
ity observed after 4-weeks’ treatment, they also benefited 
from a further, albeit small, improvement at the 2-month 
follow-up assessment. Although symptoms improved at T1 
for all patients treated with physical therapy alone, most of 
these patients experienced symptom worsening by the end 
of the 2-month follow-up period. This suggests that the 
use of physical therapy as a stand-alone treatment does not 
provide long-term pain relief from tension-type cervicalgia 
once treatment has ended.
Muscle relaxant drugs including eperisone appear to provide 
clinically significant short-term pain relief for acute (but not 
chronic) low back pain (13, 21). Indeed, eperisone 100 mg 
three times daily (t.i.d.) for 12 days (n=80) was shown to be 
effective and safe for the treatment of acute low back pain 
due to spasticity of spinal muscles with comparable anal-
gesic and muscle relaxant efficacy to thiocolchicoside 8 mg 
twice daily (n=80) (22). Treatment with eperisone 100 mg 
t.i.d. for 10 days also provided consistent beneficial anal-
gesic and muscle relaxant activity in an open-label study of 
100 patients with moderate-to-severe, acute or relapsing low 
Table II. Percentage change in patient outcome measures observed during the study period.
Eperisone + physical therapy Physical therapy alone
∆% from T0 
to T1
∆% from T1 
to T2
Total ∆% ∆% from T0 to T1 ∆% from T1 
to T2
Total ∆% 
NRS -67.2% -0.5% -67.7% -38.8% 8.1% -30.7%
NPDS -59.5% -4.2% -63.7% -34.2% 3.4% -30.8%
SF-MGPQ -60.8% -3.2% -64.0% -42.6% 5.4% -37.2%
NDI -73.5% -1.4% -74.9% -56.7% 3.9% -52.8%
Abbreviations: ∆%: percentage change; NDI: Neck Disability Index; NPDS: Neck Pain and Disability Scale; NRS: Numerical Rating Scale; SF-MGPQ: 
Short Form – McGill Pain Questionnaire.
Table III. Condition of the patients at the end of the 4-week treatment period (T1) and at 2-months’ follow-up (T2) compared 
with their previous assessment.
Eperisone + physical therapy Physical therapy alone
Improved Unchanged Worsened Improved Unchanged Worsened
T1 
NRS 50 (100%) - - 48 (100%) - -
NPDS 50 (100%) - - 48 (100%) - -
SF-MGPQ 50 (100%) - - 48 (100%) - -
NDI 50 (100%) - - 48 (100%) - -
T2
NRS 7 (14.0%) 38 (76.0%) 5 (10.0%) 2 (4.2%) 18 (37.5%) 28 (58.3%)
NPDS 40 (80.0%) 6 (12.0%) 4 (8.0%) 11 (22.9%) 8 (16.7%) 29 (60.4%)
SF-MGPQ 29 (58.0%) 15 (30.0%) 6 (12.0%) 4 (8.4%) 10 (20.9%) 34 (70.8%)
NDI 27 (54.0%) 16 (32.0%) 7 (14.0%) - 4 (8.3%) 44 (91.7%)
Abbreviations: NDI: Neck Disability Index; NPDS: Neck Pain and Disability Scale; NRS: Numerical Rating Scale; SF-MGPQ: Short Form – McGill Pain 
Questionnaire.
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back pain (23). Eperisone (50 mg t.i.d. for 14 days; n=112) 
was also effective and well tolerated compared with place-
bo (n=113) in patients with low back pain caused by acute 
musculoskeletal spasm in a randomized, double-blind, 
placebo-controlled, multi-centric study (24). Significantly 
fewer eperisone-treated patients required rescue medication 
for pain relief compared with the placebo group (p<0.001) 
demonstrating the intrinsic analgesic activity of eperisone.
Treatment with eperisone (50 mg t.i.d.; n=75) has also been 
shown to provide an immediate post-treatment benefit for 
chronic neck pain with pain in the nuchal region significant-
ly improved (p<0.005) after 6 weeks’ treatment compared 
with placebo (n=82) in patients with cervical spondylosis 
in a randomized, double-blind, clinical trial (25). Howev-
er, longer term follow-up was not reported and treatment 
effects were small (number needed to treat 37, RR 0.68 
[95% CI: 0.52–0.90]) (26).
Eperisone improves blood flow in resting skeletal muscles 
(27), which may relieve muscle hypoxia due to muscle 
contracture. Notably, a progressive decontracture of spinal 
muscles alongside a reduction in both spontaneous and 
provoked pain was demonstrated in 100 patients with 
acute low back pain and moderate contracture of the spinal 
muscles following 10 days’ treatment with eperisone 50 mg 
t.i.d. (28). In addition, significant improvement in paraspi-
nal muscle hemodynamics was demonstrated in patients 
with chronic low back pain following 4 weeks’ treatment 
with eperisone (50 mg t.i.d.; n=25) compared with phys-
ical therapy only (n=25) or McKenzie therapy (n=25), 
with improved intramuscular oxygenation during lumbar 
extension and flexion demonstrated (29). Consequently, 
the unique ability of eperisone to regulate blood supply to 
skeletal muscles may relieve the muscle stiffness and pain 
experienced by patients with tension-type cervicalgia.
The combination of antioxidants (α-lipoic acid/superox-
ide dismutase) + physiotherapy was shown to be effective 
in reducing the intensity of pain reported by patients with 
chronic neck pain compared with physiotherapy alone (30). 
The successful use of antioxidants (that target nerve inflam-
mation caused by oxidative stress) as an adjuvant therapy 
to physiotherapy suggests that a multimodal approach may 
be useful for the management of patients with neck pain. 
As such, it was of interest to assess the whether the muscle 
relaxant eperisone in combination with physical therapy 
was efficacious as a novel multimodal treatment approach.
To our knowledge this is the first study to combine 
eperisone with physical therapy for the treatment of 
tension-type cervicalgia. We show here that symptoms 
improved for 14%, 80%, 58%, and 54% of patients treat-
ed with eperisone + physical therapy based on the NRS, 
NPDS, SF-MGPQ and NDI scores, respectively, at the end 
of the 2-month follow-up compared with the end of the 
4-week treatment period. This suggests that eperisone + 
physical therapy is not only effective in alleviating pain and 
disability associated with tension-type cervicalgia during 
treatment but that these positive outcomes are maintained 
for a period of time after treatment has stopped.
Patients treated with eperisone may be adversely effected 
by gastrointestinal side effects (nausea, epigastric pain and 
vomiting), vertigo, light-headedness, dyspnea, mild somno-
lence, tremor, and dizziness (13). Importantly, no adverse 
drug events or reactions were experienced in our study. 
Indeed, a particular advantage of eperisone is its safety and 
tolerance, which has been demonstrated in a number of 
studies (22, 28, 31). In the study by Cabitza and Randelli, 
fewer adverse drug events were reported in patients treated 
with eperisone compared with thiocolchicoside (5% versus 
21%, respectively), highlighting its better tolerability (22). 
Despite comparable efficacy outcomes between eperisone 
(+ tramadol) and tizanidine (+ tramadol) in 60 patients with 
moderate-to-severe chronic low back pain associated with 
contractures of paravertebral muscles, eperisone was better 
tolerated with significantly fewer incidences of somnolence 
(16.6% versus 43.3%, respectively; p<0.05) (31). Similarly, 
no involvement of the central nervous system (i.e., somno-
lence, reduced cognitive capabilities etc.) was reported by 
Beltrame and colleagues with adverse reactions to eperisone 
limited to gastrointestinal disturbances (28). Eperisone may 
therefore be preferable to other short-acting muscle relax-
ants due to the low incidence of clinically relevant sedative 
effects on the central nervous system.
Although this study is limited by its small patient number 
and the short duration of follow-up, the combination of 
eperisone + physical therapy appears to be effective for the 
immediate and sustained relief of pain and disability asso-
ciated with tension-type cervicalgia. 
We believe that eperisone hydrochloride in synergy with 
physical therapy can be a valuable tool in the therapeutic 
management of patients suffering from tension-type cervi-
calgia. High quality, randomized, clinical trials with larg-
er patient populations and longer follow-up are needed to 
confirm the clinical benefits of eperisone + physical therapy 
for the treatment of tension-type cervicalgia.
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